Skip to content

R0041/2026-04-01/Q002/SRC05/E01

Research R0041 — Enterprise Sycophancy
Run 2026-04-01
Query Q002
Source SRC05
Evidence SRC05-E01
Type Analytical

Sycophantic clinical summaries as a patient safety risk

URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12140231/

Extract

Researchers from the University of Maryland School of Medicine identify that "sycophantic summaries could accentuate or otherwise emphasize facts that comport with clinicians' preexisting suspicions, risking a confirmation bias that could increase diagnostic error."

The FDA's guidance on non-device clinical decision support software exempts tools from medical device classification if they allow healthcare professionals to independently assess recommendations. However, researchers warn that "many clinicians may lack the time, resources, or expertise to fully evaluate these tools, potentially leading to reliance on unregulated software."

The paper calls for "transparent development of standards for LLM-generated clinical summaries, paired with pragmatic clinical studies" and notes that "large language models bring unique risks that are not clearly covered by existing FDA regulatory safeguards."

The FDA has not issued guidance specifically addressing sycophantic behavior in clinical AI tools.

Relevance to Hypotheses

Hypothesis Relationship Strength
H1 Contradicts No formal FDA requirements for sycophancy exist
H2 Supports Researchers are identifying the specific risk and calling for standards
H3 Contradicts Healthcare researchers explicitly name sycophancy as a distinct risk